Seeking Alpha

thet0nzz

thet0nzz
Send Message
View as an RSS Feed
View thet0nzz's Comments BY TICKER:
Latest  |  Highest rated
  • Did The Medicines Company Trump Cellceutix And Others In A $1B-Plus Skin Infection Market? [View article]
    I'm currently in the midst of doing DD on CTIX. Comments about safety by a previous poster, docgastro, had given me pause. However, I see that the DSMB has given the P2b trial the green light early last month (July), so that puts that concern to rest. The oft-used term, hidden gem, does come to mind with this stock. My only other concern is the quality of management. Any comments, pro or con, about this factor would be greatly appreciated. Thanks in advance.
    Aug 14 09:01 PM | Likes Like |Link to Comment
  • Is Inovio Undervalued After Positive HPV Therapy Results? [View article]
    long ino, it's called a shelf registration. It replaces a previous SR for about 120M that had been depleted to about 60M by the most recent financing in the 1Q. The SR does NOT dilute the stock until it is used. Why did INO do it now? That is the real question. It could be for negotiating strength with BP over a partnership in 3100 (and/or other INO assets). I could be for financing the P3 for 3100 for INO to go it alone. It could be for launching several new P1 or P2 trials for new indications. It could be for buying more assets such as the iTreg acquisition from Dr. Wang in China. The possibilities are manifold. Fast growing young biotechs need money, either real or potentially real. Smart companies stay ahead of the curve, which is what INO is doing.
    Jul 23 11:32 PM | 4 Likes Like |Link to Comment
  • Is Inovio Undervalued After Positive HPV Therapy Results? [View article]
    Amen
    Jul 23 09:01 PM | 2 Likes Like |Link to Comment
  • Is Inovio Undervalued After Positive HPV Therapy Results? [View article]
    Good article, William. Your last sentence sums up the INO story very nicely. Welcome to the next revolution in medicine. INO is the real deal!
    Jul 23 04:33 PM | 7 Likes Like |Link to Comment
  • 3 Biotechs Expecting Top Line Phase 2 Data Mid 2014 [View article]
    ritam...INO said "mid-year" and preferably at/during an "appropriate conference". That's as much as anyone knows.
    Apr 6 11:49 PM | Likes Like |Link to Comment
  • 3 Biotechs Expecting Top Line Phase 2 Data Mid 2014 [View article]
    INO also stated that it is looking for a timely and appropriate conference at which to announce VGX-1300 results, within the "mid-year" time period.
    Mar 26 10:08 PM | 1 Like Like |Link to Comment
  • The REAL Inovio Pharmaceuticals: An Interview With Dr. J. Joseph Kim, CEO [View article]
    Thank you, Floyd, for your excellent comments. You are an inspiration to all of us. God bless.
    Feb 21 09:05 AM | 2 Likes Like |Link to Comment
  • The REAL Inovio Pharmaceuticals: An Interview With Dr. J. Joseph Kim, CEO [View article]
    BRG:
    Thank you for a superb interview! Very intelligent and timely questions with excellent, thorough, and honest responses from Dr. Kim.
    Dr. Kim is, in my opinion, is a budding superstar CEO in biotech. When deciding to invest in biotech, the absolute #1 rule is to find a excellent, totally committed, honest, shareholder friendly CEO who puts his money where his mouth is. With Inovio, you get all of these qualities in spades...plus, the man is a true genius! On top of that, he has assembled a team that around him that is the creme de la creme in the field (and they just recently added some additional 5 star talent).
    The crooks on wall street have had some fun with INO in the past and may well try do so again in the future, but if you want to get in on the ground floor of the next Gilead/Amgen and make an investment for which your family will thank you for generations, put your money on INO! This is going to be an historic and truly GREAT company!!
    Thank you again, BRG; and, especially, thank you, Dr. Kim.
    Feb 19 09:10 PM | 9 Likes Like |Link to Comment
  • Athersys: An In-Depth Look At Its Therapies And Future Potential [View article]
    Great first article, John. Well organized and easy to read and follow. I look forward to subsequent analyses from you.

    Just a single observation. I don't believe the IBD results are due out until the second quarter.

    Thanks again and a Happy, Healthy and Successful 2014 to all!
    Dec 31 11:17 PM | Likes Like |Link to Comment
  • Tonix Is Fully Funded [View instapost]
    Thank you, Dennis. I am already in, but was unsure of the mechanics of the PRO articles. Your explanation is appreciated.
    Dec 1 08:32 PM | 1 Like Like |Link to Comment
  • Tonix Is Fully Funded [View instapost]
    Thanks for the fast response, Joe. I am on you email list and you sent me your rough draft several weeks ago. However, I am not an SA Pro subscriber. Is there any other access to the finished product? Thank you for your hard work on this stock.
    Dec 1 02:44 PM | 1 Like Like |Link to Comment
  • Tonix Is Fully Funded [View instapost]
    Hello Joe,
    Any idea what day your article on TONX will actually appear? I thought it may come out tomorrow (Mon, 12/2) given that you submitted it on Wednesday PM. Also, is it going to be for general distribution or only for SA Pro subscribers? Thank you.
    Dec 1 02:15 PM | 1 Like Like |Link to Comment
  • It's Time To Buy Tonix Pharmaceuticals [View article]
    P Man, your comments are interesting, thought provoking and much appreciated. I would like to revisit your passing comment above about preferring to put $5000 more into IMUC instead of TNXP. Would you spell out your rationale for this preference in more detail? Thank you.
    Nov 17 02:06 PM | Likes Like |Link to Comment
  • Patient, Provider, Insurer, And Government Interests Aligned For 100% Upside On Rockwell Medical [View article]
    Maybe this is why the shorts are all over RMTI. Shorts, by and large, do better research than average retail.
    Nov 16 10:59 PM | Likes Like |Link to Comment
  • Patient, Provider, Insurer, And Government Interests Aligned For 100% Upside On Rockwell Medical [View article]
    It should be mentioned that 26.3% of the float is in the hands of shorts. Whether you consider this as "rocket fuel" or as a negative, one thing for sure, this stock is going to be volatile.
    Nov 15 05:49 PM | 4 Likes Like |Link to Comment
COMMENTS STATS
26 Comments
31 Likes